 |
Glycans and glycosaminoglycans as clinical biomarkers and therapeutics. Part A / volume editor, Lijuan Zhang -- Amsterdam : Academic Press, 2019. – (58.178/P964/v.162) |
Contents
Contributors
Preface
1.
Glycan-based biomarkers for diagnosis of cancers and other diseases"
Past, present, and future
2.
Desialylation in physiological and pathological processes: New target
for diagnostic and therapeutic development
3.
Proteoglycans as miscommunication biomarkers for cancer diagnosis
4.
Fucosylation in cancer biology and its clinical applications
5.
The sensitivity and specificity of serum glycan-based biomarkers for
cancer detection
6.
Retrospective analysis of glycan-related biomarkers based on clinical
laboratory data in two medical centers during the past 6 years
7,
Serum SCCA levels in patients suffering cancers or other diseases
8.
Increased serum CA724 levels in patients suffering gout vs cancers
9.
Serum CA5O levels in patients with cancers and other diseases
10.
Serum AFP levels in patients suffering from 47 different types of
cancers and noncancer diseases
11.
Serum CEA levels in 49 different types of cancer and noncancer diseases
12.
CA242 as a biomarker for pancreatic cancer and other diseases
13.
Serum CA125 levels are decreased in rectal cancer but increased in
fibrosis-associated diseases and in most types of cancers
14.
Serum CA199 levels are significantly increased in patients suffering
from liver, lung, and other diseases
15.
Serum CA153 as biomarker for cancer and noncancer diseases
16.
Fasting blood glucose levels in patients with different types of
diseases
17.
HbA1c: High in acute cerebral infarction and low in brain trauma
18.
Glycated albumin level is significantly decreased in patients suffering
nephrotic syndrome
19.
Glycated serum proteins: High in pancreatic cancer and low in
preeclampsia
20.
The serum SA levels are significantly increased in sepsis but decreased
in cirrhosis
21.
Serum a-L-fucosidase activities are significantly increased in patients
with preeclampsia
22.
Glucuronidated bilirubin: Significantly increased in hepatic
encephalopathy
23.
Serum PSA levels in patients with prostate cancer and other 33 different
types of diseases
Index
